RT Journal Article
T1 Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation.
A1 Mostaza, Jose María
A1 Suarez, Carmen
A1 Cepeda, Jose María
A1 Manzano, Luis
A1 Sánchez, Demetrio
A1 PERFILAR study investigators, 
K1 Antithrombotic treatment
K1 Direct-acting oral anticoagulants (DOACs)
K1 Nonvalvular atrial fibrillation (NVAF)
K1 Vitamin K antagonists (VKAs)
AB This study assessed the sociodemographic, functional, and clinical determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation (NVAF) attended in the internal medicine setting. A multicenter, cross-sectional study was conducted in NVAF patients who attended internal medicine departments for either a routine visit (outpatients) or hospitalization (inpatients). A total of 961 patients were evaluated. Their antithrombotic management included: no treatment (4.7%), vitamin K antagonists (VKAs) (59.6%), direct oral anticoagulants (DOACs) (21.6%), antiplatelets (6.6%), and antiplatelets plus anticoagulants (7.5%). Permanent NVAF and congestive heart failure were associated with preferential use of oral anticoagulation over antiplatelets, while intermediate-to high-mortality risk according to the PROFUND index was associated with a higher likelihood of using antiplatelet therapy instead of oral anticoagulation. Longer disease duration and institutionalization were identified as determinants of VKA use over DOACs. Female gender, higher education, and having suffered a stroke determined a preferential use of DOACs. This real-world study showed that most elderly NVAF patients received oral anticoagulation, mainly VKAs, while DOACs remained underused. Antiplatelets were still offered to a proportion of patients. Longer duration of NVAF and institutionalization were identified as determinants of VKA use over DOACs. A poor prognosis according to the PROFUND index was identified as a factor preventing the use of oral anticoagulation.
YR 2021
FD 2021-08-09
LK https://hdl.handle.net/10668/24948
UL https://hdl.handle.net/10668/24948
LA en
DS RISalud
RD Apr 6, 2025